Introduction: Serum ferritin was demonstrated to be a useful tool to predict the risk in patients who undergo hematopoietic stem cell transplantation (HCT). Still it is not clear if its predictive value solely represents iron overload (IO) and published results are sometimes contradictory. So the objective of present study was to determine relationship between elevated pre-HCT serum ferritin levels, morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HCT) on one side, and its correlations with various risk indexes which were developed recently to predict outcomes after allo-HCT on the other side.
INTRODUCTION
Iron overload is common in patients undergoing allogeneic hematopoietic stem cell transplantation (HCT). The main causes of IO in HCT are prolonged dys-erythropoiesis, increased intestinal iron absorption due to anemia and chemo-therapy associated mucositis which leads to increased iron absorption, transfusion burden and release of iron from injured tissues [1] .
Many studies have shown an association between elevated serum ferritin before HCT (used as a surrogate measure of iron overload) and adverse outcomes [7] [8] [9] [10] 13] , mostly from an increase in infection risk [2] [3] [4] [5] [6] [7] and non-relapse mortality (NRM) [7, 8] , although some of these studies also suggested an association between IO and acute graft versus host disease (GvHD) [9, 10] or hepatic veno-occlusive disease (VOD) [12] . However, these studies were retrospective and mostly based on surrogate measures of iron burden, especially serum ferritin.
Different cutoffs ferritin was used in several studies, e.g., (Altes et al. 2002 (F 3000) [23] ; Armand et al. 2007 Armand et al. (F 2515 [24] ; Kataoka et al. 2009 (F 599) [8] ; Mahindra et al. 2009b Mahindra et al. (F 1910 [9] ; Lee et al.2009 (F 1000) [26] ; Sucak et al. 2010 (F 500) [7] , so the optimal cutoff ferritin which accurately reflects increased risk of complications after HCT is not well estimated.
In the other hand when pre-transplant IO was measured using liver magnetic resonance imaging (R2-MRI), found contradictory results. There was no association between pre-transplant IO defined by R2-MRI measured liver iron concentration (LIC) and overall survival (OS), NRM, relapse rate, GvHD, bacterial, viral or fungal infections [14, 15] . This results doesn't contradict the previous data that used serum ferritin for assessment of IO, because these studies had limited number of patients included and small studies in HCT usually have limited power to demonstrate the impact of single factor, like IO, on the outcomes. So ferritin level is still accepted as a standard risk assessment tool in HCT recipients.
Many accepted risk indexes likes; Disease risk index(DR), Hematopoietic cell transplantation comorbidity index (HCT-CI), European Group for Blood and Marrow Transplantation (EBMT) risk score and Pre-transplant Assessment of Mortality Score (PAM) were developed to predict outcomes and complications of allo-HCT [17] [18] [19] [20] . Some of them include parameters that could be attributed to IO, but there is limited data on correlation between these indexes and ferritin levels.
Summarizing, a substantial number of studies have been published on the topic of serum ferritin in HCT, but still there are several controversial points. So we focused our study on the impact of pre allo-HCT serum ferritin on different events post allo-HCT; Early infectious complications, mucositis, engraftment, venooclusive disease, GvHD, and on determining the optimal cutoff for increased risk of complications and mortality. Also we evaluated how a serum ferritin level was correlated with the other tools of HCT risk assessment, like pre-transplant indexes.
MATERIALS AND METHODS
We have retrospectively evaluated a group of one hundred and six consecutive patients who underwent unmanipulated allo-HCT in R. The cohort included 52 men and 54 women with a median age at transplantation of 31.8 (range, 5 to 60) years. Underlying diseases were acute myeloid leukemia (n=78), myelodysplastic syndrome (n= 12), primary myelofibrosis (n=3), aplastic anemia (n=11) and B-thalassemia major (n=2). Stem cell transplants were from HLA-identical siblings (n=26), haplo-identical (n=9), or unrelated volunteer donors (n=71). The conditioning regimens were myeloablative (MAC) in 26 patients, and reduced intensity (RIC) in the rest of this group. The study was approved by the Institutional Review Board at the St.Petersburg State Pavlov Medical University. Each patient has given an informed consent for the use of personal data. The median follow-up period was 12 (range, 4-27) months after allo-HCT. Baseline characteristics of the patients are given in ( Table 1) .
Mucositis was graded on a scale of 0 to 4, according to Common Toxicity Criteria, version 4, from the National Cancer Institute. The International Consensus on opportunistic fungal infections was established by the EORTC/MSG [16] . Bacterial infection was defined as recovery of a recognized pathogen from, at least, 2 blood or urine cultures yielding the same organism. For each patient, the numbers of bacterial, viral and fungal infections were calculated, according to CIBMTR Instructions for 100 Days post-HCT (Data Form 2100). Document Number: A00531 version 1.1 (7/20/2012). Neutrophil recovery was defined as an ANC of 500/μL for the first 3 consecutive days. (DR) index, (HCT-CI), (EBMT) risk and (PAM) scores were calculated according to Armand et al. [17] , Sorror ML et al. [18] , A Gratwohl [19] and Parimon T et al. [20] , respectively. PAM score and DR index were calculated only in malignant diseases. Acute GvHD was graded according to Gratwohl criteria [21] . Graft-vs-host disease -relapse free survival (GRFS) was considered according to Shernan G. Holtan, et al. [22] . A diagnosis of sinusoidal obstruction syndrome (Hepatic veno-occlusive disease) was made on the basis of Seattle criteria, as described by McDonald et al. [11] . Continuous variables in the 2 groups were compared by means of the Mann-Whitney test. Categorical variables were compared using the Chi-square test. GRFS, OS, NRM and event-free survival (EFS) were calculated using the Kaplan-Meier method. Possible risk factors were tested using the logrank test. Relapse was counted as competing risk for non-relapse mortality. Cutoff levels of ferritin amounts were determined using ROC -analysis. The association between serum ferritin levels and different risk indexes (DR, EBMT, HC-CI and PAM score) was calculated according to Kruskal-Wallis Test. Correlation between ferritin and C-reactive protein (CRP) was evaluated using Spearman method. The calculations were made with SPSS software (version 17). 
RESULTS
According to the area under the curve (AUC) and with using receiver operating characteristic curve (ROC) analysis in many indexes like febrile neutropenia, bacterial infections, fungal infections, pneumonia, NRM and OS, the cutoff of ferritin was between 412.2 to 612 ng/mL for infectious complication and 737 ng/mL for NRM & OS ( Table 2) .
As the cutoffs the majority of infectious complications was near the 500 ng/mL value, which is in the literature considered moderate IO, we used it to analyze infectious complications, mucositis, febrile neutropenia, graft engraftment, hemorrhagic cystitis and number of RBC units transfused after allo-HCT. For NRM and OS analysis we used the higher cutoff 737 ng/mL, which was determined statistically.
Sixty-three (59.4%) patients (pts) had increased serum ferritin concentrations ( 500 ng/mL), and were classified as the high-ferritin group (HF), with a median of 1134.8 ng/mL (range, 511-4247). The rest of patients (n=43, 40.6%) were classified as LF group, and had serum ferritin concentrations (<500 ng/mL) with a median ferritin at 281.8 ng/mL (range, 12.1-466.3).
Active infections within last month prior to HCT were observed only in HF group. There were sixteen cases; (8) pts with probable invasive pulmonary aspergillosis, (5) pts with bacterial infections, (2) pts with fever of unknown origin and (1) 
Febrile Neutropenia
Febrile neutropenia was observed in eighty cases; 51(81%) in HF and 29 (67.4%) in LF (P > 0.05). Despite the lack of a statistically significant difference between the groups, we revealed a linear correlation between increasing ferritin level and numbers of febrile neutropenia episodes. The median for HF group was 1.4 febrile episodes/ patient (rang, 0 to 6) vs 0.9 (0 to 3) in LF patients, P = 0.02; [OR], 2.87; 95% [CI], (1.14-7.21). In the same context, the number of patients who required granulocyte colony-stimulating factor (G-CSF) injections to boost hematopoiesis and to shorten neutropenic period was; 30 (47.3%) vs 9(21%) in the HF and LF groups, respectively, P =0.007; [OR], 3.4 ; 95% [CI], (1.14-8.3).
Bacterial Infections
Although the percentage of patients exposed to bacterial infections was similar in both HF and LF groups (resp., 85.7, 84.2%), there was a distinct correlation between the increased pre-HCT ferritin and median number of infectious episodes/ patient, i.e., 2.6(0 to 7) in HF group, and 2.0 (0 to 6) in LF sample, P = 0. 
Fungal Infections
In our cohort study, fungal infections were observed in 12 pts (19%) of HF group and 3 pts (7%) in LF group, with no statistically significant difference P =0.06, [OR], 3,1; 95%[CI], (0.8-11.8).
Cytomegalovirus(CMV) Infections
During the early period after allo-HCT, CMV reactivation was observed in 40 pts (37.7% of total), including 25 and LF groups, respectively. No statistically significant difference was observed in platelet recovery , P> 0.05.
Hepatic Veno-Occlusive Disease (VOD)
Only 4 cases were observed in total cohort; 3 in HF and 1 in LF group. The pre-HCT ferritin levels in these cases were as follows; 4247, 1631, 827.3, 112 ng/mL, and one case with primary myelofibrosis had severe VOD with multiorgan failure, and died on D7+ after transplantation.
Acute and Chronic Graft-Versus-Host Disease (GvHD)
Acute GvHD grade I-II and grade III-IV was diagnosed in 23 pts (37%) and 6 (9.5%) in HF vs 19 pts (44.2%) and 2 (4.6%) in LF, respectively. This difference was not statistically significant, P =0.46. The cumulative incidence of extensive chronic GvHD at 1 year after transplantation was 16% in HF and 28% in LF without reaching statistically significant, P =0. The results of analysis regarding early and infectious complications are summarized in Figure 1 
One Year Outcomes of Allo-HCT
With the estimated cutoff level 737 ng/mL the cumulative incidence of NRM within one year was higher in HF (25%) than in LF (10.3 %), P =0.024. The same pattern was observed for OS; 85% in LF vs 63% in HF, P = 0.002. On the contrary, there was no statistical differences in EFS and GRFS between HF and LF groups; 54% vs 66% (P =0.14) for EFS and 40% vs 45% (P =0.4) for GRFS. However, on multivariate analysis we found that donor other than matched related (MRD) was the only factor that was associated with higher NRM and lower OS, P =0. The results of outcomes (NRM, OS, EFS and GRFS) analysis are summarized in Figure 2 (a,b,c,d )
Correlation of the pre-HCT serum ferritin and Creactive protein (CRP)
To exclude that the elevated pre-transplant ferritin was not due to IO, but the systemic inflammatory response (SIRS), we analyzed the association between serum ferritin and pre-transplant CRP levels. There was no statistically significant correlation between CRP> 5 and ferritin levels (P =0.055). So the observed differences in early complications based on ferritin level were not associated with presence of SIRS pre-HCT, but more likely due to IO. 
Associations between pre allo-HCT ferritin levels and different risk indexes
Surprisingly, we found statistically significant association between pre-transplant ferritin and all currently existing risk assessment indexes; EBMT score (P =0.0001), comorbidity index (HCT-CI) (P =0.003), Pre-transplant Assessment of Mortality Score (PAM) (P =0.007) and disease risk (DR)(P =0.037). Despite, absence of a clear trend of increasing ferritin in risk groups from different scoring systems, there was a clear evidence of lower ferritin level in patients with lowest risk. Also there was a positive correlation between the ferritin level and PAM (r2=0.047, Figure  3 ).
DISCUSSION
IO associates with increased susceptibility to different infections. Iron deprivation was found to be the key factor in the antimicrobial host defense. Several previous studies showed the impact of elevated serum ferritin on the increasing the incidence of bacterial, blood stream, fungal infections [25, 27, 28] and pneumonia [7] post allo-HCT. On the contrast, latest recent study, M Tanaka1 et al. [29] , showed that the cumulative incidence of infection within 100 days after HCT, was not different between the two groups with (cutoff >1000 ng/mL). In our study we found that elevated ferritin more than 500 ng /mL pre allo-HCT associated with increasing number of febrile neutropenia episodes (P =0.02), increasing number of bacterial episodes, increased pneumonia incidence, predominantly the bacterial one. The observed results reflect a well-known negative effect of IO on antiinfectious immunity [31] [32] [33] [34] . In contrast to the published studies we didn't find increased incidence of fungal infections, that may be related to aggressive center policy in pre-transplant fungal infection screening and secondary prophylaxis [35] . Also in accordance with published studies we found delayed engraftment and increased percentage of patients who required G-CSF stimulation in HF group [29] .
Also in this study we observed that patients who had high pre allo-HCT ferritin levels needed more blood transfusions than those who were in LF group. This may be explained in part by the presence of antibodies in heavily transfused patients [39] and by increasing incidence of febrile neutropenia and bacterial infections. In these inflammatory conditions the hepcidin is secreted as a defensive mechanism, which causes inhibition of iron realizing from its stores and thus prevents use iron in normal hematopoiesis and leads to slower recovery of erythroid lineage after HCT [40] . History of heavy blood transfusion 20 RBC units in last year before transplantation was recorded in 14 pts, the median ferritin levels in these pts was 1464.5 ng/mL (range, 650-4247). Only 3 patients were on chelation therapy with Exjade at the date of allo-HCT and they discontinued it just prior conditioning regimen.
Interestingly, the statistical cutoffs for infectious complications and delay in the engraftment were lower (>500 ng/mL), than in published papers [3, 4, [8] [9] [10] , which was usually 1000-3000 ng/mL. This may raise the question that some of the patients with moderate elevation of ferritin may have not the actual IO, but the systemic inflammatory response (SIRS) pre-transplant. Several studies postulated that moderately increased ferritin is associated with SIRS in the HCT and non-HCT setting [30, 41] , but in our patient series we found no correlation between CRP and ferritin. Furthermore, CRP level was not statistically different in patients with ferritin above or below 500 ng/mL. So this may indicate that even moderate IO may be associated with increased incidence of complications in HCT recipients and may advocate use of chelation therapy before HCT in patients with lower level of ferritin than 1000-2000 ng/mL. This observation should be confirmed with large, adequately powered studies with MRI assessment of IO.
Many studies have shown an association between elevated serum ferritin before HCT (used as a surrogate measure of IO) and adverse overall survival [7] [8] [9] [10] 13, 29] and NRM [7, 8] . These studies used various cutoff levels (500-3000 ng/mL). On the other hand when pre-transplant IO was measured with MRI, there such differences were not observed in the two studies; Trottier et al, found no association between pre-transplant IO defined by R2-MRI measured LIC and OS, NRM, relapse rate or GvHD [14] , similar results have been reported by Armand et al. [15] . In our study in multivariate analysis we found no association between pre-transplant ferritin, NRM and OS, although in univariate, the significant differences were observed. This may be due to relatively small group size and heterogeneity of indications for HCT and conditioning regimens. Partly, this is confirmed by the strong observed correlation between ferritin levels and all of the HCT risk assessment indexes, including EBMT, HCT-CI, DR, PAM. As all of them were developed using very large cohorts of patients, with larger study group, the observed differences in NRM and OS in HF and LF groups might have reached the statistical significance.
Furthermore, based on analysis of ferritin and transplant indexes, several interesting conclusions could be drawn. On the one hand, we found association between ferritin and NRM predictive indexes, like HCT-CI and PAM. These scoring systems include such parameters as liver, heart, kidney and lung dysfunction and infectious complications that at least partially may be associated with IO [36] [37] [38] . Indeed in our recurrent infections and liver dysfunctions were more common in HF group. So IO is one of the factors that increase the risk of HCT predicted by HCT-CI and PAM. On the other hand, pre-transplant ferritin was associated with DR scores, which indicates that some proportion of the risk is not due to IO, but due to underlying disease itself, higher number of previous chemotherapy courses and poorer status at the time of HCT.
In conclusion, as was previously published, we observed increased incidence of infectious complications and adverse impact on engraftment, but also found that lower level of ferritin is associated with increased risk of these events. Also association of ferritin levels with major HCT mortality risk indexes, makes it simple and effective tool to predict the outcome of treatment.
